Skip to main content

Advertisement

Table 2 General characteristics in control, diabetic, and diabetic treated with low and high doses of exenatide

From: Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

  C D DTL DTH
Number 7 10 10 9
Plasma glucose (mM) 4.31 ± 0.72 29.86 ± 1.32* 29.08 ± 1.20* 28.66 ± 0.89*
Plasma Insulin (Iu/ml) 19.36 ± 0.58 4.91 ± 0.27* 5.06 ± 0.30* 5.19 ± 0.31*
Plasma total cholesterol (mM ) 1.46 ± 0.38 2.79 ± 0.29* 2.77 ± 0.50* 2.27 ± 0.72a*,#
Plasma triglycerides (mM ) 0.83 ± 0.13 1.42 ± 0.20* 1.29 ± 0.27* 1.08 ± 0.87#
Plasma free fatty acid (mM ) 1.45 ± 0.20 2.60 ± 0.41* 2.26 ± 0.63* 1.53 ± 0.34#,$
Body weight (g) 459.57 ± 86.52 207.70 ± 48.89* 200.60 ± 74.48* 211.11 ± 41.20*
Heart weight (g) 1.30 ± 0.17 0.93 ± 0.29* 0.85 ± 0.20* 0.88 ± 0.23*
Heart/body weight (g/kg) 2.86 ± 0.38 4.50 ± 0.68* 4.42 ± 0.76* 4.42 ± 0.86*
  1. Values were obtained at sacrifice, after administration with or without 8 weeks of exenatide treatment. Control (C), diabetic (D), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH). All values were expressed as mean ± S.E.M. *P < 0.05 or 0.01 vs. C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.